The Bioscience & Technology Business Center has assisted over 40 early-stage technology companies in a wide variety of areas ranging from market feasibility and raising capital to business plan development and strategic planning. Over the past seven years, its clients have raised more than $180 million in investment capital and created over 100 net new jobs with an average salary twice that of the local private sector wage.
The BTBC is different from other incubators.
“It is the goal of the BTBC to be more than a life sciences laboratory facility. “Matthew McClorey, BTBC Director, says. “We want to provide more than bricks and mortar. We want the BTBC to become the hub of entrepreneurial activity for the region – a place where entrepreneurs can share ideas, innovate together and grow successful businesses.”
Here are examples of the business development services available to BTBC tenants:
Business Development Services
From corporate formation to exit strategy, the BTBC has the expertise, tools and dedication necessary to help entrepreneurs and start-up technology companies grow and prosper. The following are examples of the business development services available to BTBC tenants:
- Corporate Formation
- Market Research & Analysis
- Competitor Research & Analysis
- Business Plan Writing
- Grant Proposal Writing
- Strategic Planning
- Business Model Development
- Revenue Model Development
- Organizational Modeling
- Sales & Marketing
- Financial Strategy
- Capital Acquisition
- Financial Management
- Operations Management
- Accounting Services
- Business Valuation
- Exit Strategy
Additional BTBC Services
- Networking Events
- Entrepreneurial Roundtables
- Monthly Seminars
Seminars
- Raising Capital
- Business Valuation
- Intellectual Property Protection
- Employee Stock Option Plans
- Sales and Marketing
- Internet Sales and Marketing
- Advertising and Public Relations
- The Drug Development Process
- Employee Benefits
Access to Capital
Federal Money
- SBIR Grant Applications
State Money
- Kansas Bioscience Authority
- Kansas Technology Enterprise Corporation
Local Money
- Private Investor Network and Contacts
- Mid-America Angels
- Midwest Venture Alliance (MVA)
- Various Venture Capital Firms
BTBC Client Success Stories
“The rapid progress that Deciphera Pharmaceuticals has enjoyed has been largely due to the dedication and availability of the BTBC team. Thank you BTBC!”
—Daniel flynn, President Deciphera Pharmaceuticals Lawrence, Kansas
Lilly Inks Multimillion-Dollar Deal for Deciphera’s Preclinical Oncology Program
Eli Lilly licensed Deciphera Pharmaceuticals’ preclinical B-Raf kinase inhibitor program in oncology therapeutics in a deal worth $520 million in milestone payments. Deciphera will receive an upfront payment and research funding for two years in exchange for giving Lilly worldwide rights to any drug developed from this collaboration.The agreement covers four project areas involving selective or multikinase targeted B-Raf inhibitors. Deciphera, which will use its phylomechanics discovery platform, stands to earn up to $130 million per program in development, regulatory, and sales milestones. If a product is commercialized, Deciphera will also be entitled to royalties….
Novartis Options Proteon Therapeutics for $550M
Proteon Therapeutics has more than $550 million riding on its mid-stage trial of its blood-vessel dilating therapy. That’s how much Novartis has agreed to pay for the company–in an upfront payment and milestones–provided the trial ends successfully. And Proteon got more good news with the announcement that MPM Capital has led a $38 million investment round for the company, which will fund the company through that Phase II milestone.
The Series B financing includes new investors, the MPM Bio IV NMS Strategic Fund L.P. and the Vectis Healthcare & Life Sciences Fund, along with existing investors TVM Capital, Skyline Ventures, Prism VentureWorks, Intersouth Partners and several of Proteon’s original angel investors.
